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Abstract  
The list of conditions related to magnesium deficiency is quite high. The National Institute of Health information says that 
magnesium is a wonder drug but its use in clinical medicine is very scarse. Magnesium deficiency has been implicated in a 
wide range of clinical conditions such as insomnia, crumps, diarrhea, erectile dysfunction, headache, migrane, low blood 
pressure, loss of appetite, nausea, vomiting, weakness, numbness, tingling, seizures, personality change, abnormal heart 
rhythms, coronary spasms, cardio vascular disease, type 2 diabetes mellitus, depression, immune dysfunction, thyroid 
function alterations to name a few. Although supplementation is said to restore normalcy in a majority of cases, very few 
studies have been done in this direction. The role of magnesium in alleviating cancers of all types has been extensively 
studied, but treatment using magnesium is very limited. This review article aim to bring out research findings during the last 3 
decadeson the role magnesium in health and disease and this will enable researches to understand in detail and give 
awareness about further works to be carried out in this field, with an ultimate aim of using magnesium as a drug to cure a 
host of diseases.  
Keywords: Magnesium, CVD, DM, lipid, MCI, renal failure, liver disease, reproductive, depression, cancer, thyroid, immune, 
alchool. 
 
INTRODUCTION 
There is power and force in magnesium that cannot be equaled 
anywhere in the world of medicine. There is no substitute for 
magnesium in human physiology; nothing comes close to it in terms 
of its effect on overall physiology. Without sufficient magnesium, the 
body accumulates toxins and acid residues, degenerate rapidly and 
ages prematurely (1). It goes against a gale wind of medical science 
to ignore magnesium chloride usedtransdermally in the treatment of 
any acute or chronic disorder, especially cancer. Over 300 different 
enzyme systems relay upon magnesium to facilitate their catalytic 
action, including ATP metabolism, creatine kinase activation, 
adenylatecyclase glutathione synthetase, Na-K-ATPase (2) and DNA 
& RNA transcription and repair (1). 
Magnesium deficiency has been implicated in a host of clinical 
disorders but the medical establishment just cannot get through its 
thick skull that it is an important medicine. In this article, the host of 
organ functions and every known type of disease that are looked to 
the metal magnesiumare being highlighted. It makes perfect medical 
sense to saturate the body with magnesium through transdermal 
means. Magnesium is the mineral of rejuvenation and prevents the 
calcification of our organs and tissues that is characteristic of the old 
age related degeneration of our body. 
 
MAGNESIUM AND CARBOHYDRATE METABOLISM 
 
The interrelationships between magnesium and carbohydrate 
metabolism have regained considerable interest over the last few 
years. Insulin secretion requires magnesium: magnesium deficiency 
results in impaired insulin secretion while magnesium replacement 
restores insulin secretion. Furthermore, experimental magnesium 
deficiency reduces the tissues sensitivity to insulin. Subclinical 
magnesium deficiency is common in diabetes. Some studies suggest 
that magnesium deficiency may play a role in spontaneous abortion 
of diabetic women, in fetal malformations and in the pathogenesis of 
neonatal hypocalcemia of the infants of diabetic mothers. 
Administration of magnesium salts to patients with type 2 diabetes 
tends to reduce insulin resistance (3). 
Magnesium is an important ion in all living cells being a cofactor 
of many enzymes, especially those utilising high energy phosphate 
bonds. The relationship between insulin and magnesium has been 
recently studied. In particular it has been shown that magnesium 
plays the role of a second messenger for insulin action; on the other 
hand, insulin itself has been demonstrated to be an important 
regulatory factor of intracellular magnesium accumulation. 
Conditions associated with insulin resistance, such as hypertension 
or aging, are also associated with low intracellular magnesium 
contents.Regular magnesium supplementation can contribute to an 
improvement in both islet Beta-cell response and insulin action in 
non-insulin-dependent diabetic subjects (4). 
Enzymatic reactions involving the transfer of high-energy 
phosphate require a divalent metal ion as a participant. This is 
normally Mg2+ in biological situations, as its level within the cell is 
greater than other divalent metal ions. There is a growing body of 
evidence that its concentration is relatively low, approximately 0.5 
mM. This low level permits control of important parts of carbohydrate 
metabolism, especially glycolysis, by Mg2+ (5).  
Magnesiumis an important coherent controller of glycolysis and 
the Krebs cycle. Many of the glycolytic enzymes are sensitive to 
Mg2+. The most important effect is due to MgATP2-being a cofactor 
for a number of these enzymes while other chelation forms are 
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inactive or inhibitory (6).  
A role for intracellular Mg deficiency in the development of insulin 
resistance and suggest that the effect occurs at a site(s) distal to 
glucose entry into the cell. The effect of Mg deficiency on insulin 
action appears to be reversible (7). 
 
MAGNESIUM AND DIABETIS MELLITIS 
 
A significant inverse association between magnesium intake and 
diabetes risk. This study supports the dietary recommendation to 
increase consumption of major food sources of magnesium, such as 
whole grains, nuts, and green leafy vegetables (8). 
Oral magnesium replacement therapy corrects hypomagnesemia 
after a minimum treatment period of 3 months. These observations 
might be important for the prevention of diabetic late complications 
(9). 
Hypomagnesemia has been reported to occur at an increased 
frequency among patients with type 2 diabetes compared with their 
counterparts without diabetes. Hypomagnesemia occurs at an 
incidence of 13.5 to 47.7% among patients with type 2 diabetes. 
Poor dietary intake, autonomic dysfunction, altered insulin 
metabolism, glomerular hyperfiltration, osmotic diuresis, recurrent 
metabolic acidosis, hypophosphatemia, and hypokalemia may be 
contributory. The increased incidence of hypomagnesemia among 
patients with type 2 diabetes presumably is multifactorial. Because 
current data suggest adverse outcomes in association with 
hypomagnesemia, it is prudent to monitor magnesium routinely in 
this patient population and treat the condition whenever possible (10). 
Diabetes mellitus is the most common pathological state in which 
secondary magnesium deficiency occurs. Retinopathy and 
microangiopathy are correlated with the drop of plasma and red 
blood cell Mg. K deficiency increases the noxious cardiorenal effects 
of Mg deficiency. The treatment should primarily insure diabetic 
control (11). 
Intracellular magnesium concentration is low in type 2 diabetes 
mellitus and in hypertensive patients. In patients with type 2 diabetes 
an inverse association exists between the plasma magnesium and 
insulin resistance due to intracellular changes.Magnesium is required 
for both proper glucose utilization and insulin signaling. Metabolic 
alterations in cellular magnesium, which may play the role of a 
second messenger for insulin action, contribute to insulin resistance 
(12). 
Magnesium deficiency, both extracellular and intracellular, is a 
characteristic of chronic stable mild Type 2 diabetes, and as such, 
may predispose to the excess cardiovascular morbidity of the 
diabetic state. Mg-io measurements may provide a more readily 
available tool than has heretofore been available to analyse 
magnesium metabolism in a variety of diseases (13). 
In all diabetics plasma magnesium concentrations were inversely 
related to plasma glucose values (rs = -0.33; p less than 0.01) and in 
non-insulin-treated patients to plasma insulin concentrations (rs = -
0.28; p less than 0.05), the former confirming previous observations. 
Direct relation of plasma magnesium concentration with glucose 
disposal was unexplained by its influence on insulin secretion but 
was related to insulin sensitivity; hence magnesium may be an 
important determinant of insulin sensitivity in maturity onset diabetes 
(14). 
Experimental studies in animals and cross-sectional studies in 
humans have suggested that low serum magnesium levels might 
lead to type 2 diabetes; however, this association has not been 
examined prospectively. A graded inverse relationship between 
serum magnesium levels and incident type 2 diabetes was observed. 
From the highest to the lowest serum magnesium levels, there was 
an approximate 2-fold increase in incidence rate (11.1, 12.2, 13.6, 
12.8, 15.8, and 22.8 per 1000 person-years; P = .001). No 
association was detected between dietary magnesium intake and the 
risk for incident type 2 diabetes in black or white participants. Low 
serum magnesium level is a strong, independent predictor of incident 
type 2 diabetes. That low dietary magnesium intake does not confer 
risk for type 2 diabetes implies that compartmentalization and renal 
handling of magnesium may be important in the relationship between 
low serum magnesium levels and the risk for type 2 diabetes (15). 
The magnesium deficiency has been associated with chronic 
diseases, amongst them, diabetes mellitus. Epidemiological studies 
had shown low levels of magnesium ingestion in the general 
population, as well as a relation between the ingestion of food rich in 
magnesium and the reduction of diabetes installation and its 
complications. Hypomagnesemia is frequently present in diabetic 
patients, however there is not an exact elucidation of the mechanism 
of magnesium deficiency in diabetes mellitus. The supplementation 
with magnesium has been suggested in patients with diabetes 
mellitus who have proven hypomagnesemia and the presence of its 
complications (16). 
 
MAGNESIUM AND PROTEIN METABOLISM 
 
Magnesium is an essential cofactor for the synthesis and salvage of 
purine and pyrimidine nucleotides. It plays important roles in the 
structure of nucleic acids and affects their interaction with proteins 
and other ligands. Magnesium is required for DNA replication, 
transcription into RNA and translation into protein. In spite of the 
diverse roles of magnesium in these fundamental 
processes, metabolic regulation by magnesium has not been 
observed. Its role in the regulation of cell growth, division and 
differentiation remains uncertain (17). 
MAGNESIUM AND LIPID METABOLISM 
 
In plasma, magnesium deficiency increased triglyceride and free 
cholesterol levels and decreased esterified cholesterol levels. Rats 
fed a magnesium-deficient diet containing sucrose showed 
particularly high triglyceride plasma levels. In liver, magnesium-
deficient rats fed sucrose showed a significant increase in 
triglycerides, lactate and a-glycerophosphate and a significant 
decrease in glycogen. With magnesium deficiency, triglycerides were 
significantly increased in the very low density lipoprotein (VLDL) and 
low density lipoprotein (LDL) fractions and cholesterol levels were 
increased in the VLDL and LDL and significantly lower in the high 
density lipoprotein (HDL) fractions. The detrimental effect of severe 
magnesium deficiency associated particularly with a high 
carbohydrate diet content and more especially with a sucrose diet is 
discussed (18). 
Mg(2+) deficit and the lower blood concentration of Mg(2+) was a 
frequent in patients with the main risk factors, hyperlipidemia, 
hypertension, diabetes, and obesity. Magnesium is necessary the 
activity of lecithin cholesterol acyltransferase (LCAT) and lipoprotein 
lipase (LPL), which lowers triglyceride levels and raises HDL-
cholesterol levels (19).  
One of the factors involved in accelerated atherosclerosis in 
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hemodialysis patients is dyslipidemia. Magnesium does not appear 
to increase lipoprotein synthesis. It may be involved in the regulation 
of some enzymes responsible for lipoprotein synthesis.  The 
correlation of serum magnesium and triglyceride that was found 
could be due to changes in hepatic triglyceride metabolism, as 
lipoprotein (a) is a factor involved in accelerated atherosclerosis.  Its 
association with serum magnesium could be important in 
hemodialysis patients (20).  
Epidemiological and experimental studies have shown 
that magnesium is closely related to regulation of lipid metabolism, 
membrane structure and permeability, ion migration through cellular 
membranes, endocrine hormone and platelet function. Plasma from 
cardiac catheterized patients suffering from chest pains contained 
higher levels of oxysterols than age and sex matched patients free of 
chest pain. Studies with cultured arterial cells in media deficient 
in magnesium or containing oxysterols indicated that 
both magnesium and oxysterols have an important role in 
lipid metabolism in patients with coronary heart disease (21). 
MAGNESIUM AND MYOCARDIAL INFARCTION 
 
Mechanisms underlying cardiac fibrogenesis in magnesium 
deficiency are unclear. It was reported earlier from this laboratory 
that serum from magnesium-deficient rats has a more pronounced 
stimulatory effect on cell proliferation, net collagen production, and 
superoxide generation in adult rat cardiac fibroblasts than serum 
from rats on the control diet. Circulating and cardiac tissue levels of 
angiotensin II were significantly elevated in magnesium-deficient 
animals (67.6% and 93.1%, respectively, vs. control). Plasma renin 
activity was 61.9% higher in magnesium-deficient rats, but serum 
angiotensin-converting enzyme activity was comparable in the two 
groups. Furthermore, preliminary experiments in vivo using enalapril 
supported a role for angiotensin II in magnesium deficiency. There 
was no significant difference between the groups in serum 
aldosterone levels. The findings suggest that circulating angiotensin 
II and aldosterone may stimulate fibroblast activity and contribute to 
a fibrogenic response in the heart in magnesium deficiency (22). 
The higher the lymphocyte potassium concentration, the greater 
the reduction in the incidence of arrhythmias. Serum magnesium 
levels increased by 16.5% and lymphocyte magnesium 
concentrations by 72% in the magnesium treated group. Intravenous 
magnesium reduces the incidence of serious arrhythmias after acute 
myocardial infarction. Serum magnesium levels increased by 16.5% 
and lymphocyte magnesium concentrations by 72% in the 
magnesium treated group. Intravenous magnesium reduces the 
incidence of serious arrhythmias after acute myocardial infarction 
(23). 
Intracellular magnesium ([Mg]i) plays an important role in the 
regulation of myocardial metabolism. Sublingual epithelial cell 
[Mg]i correlates well with atrial [Mg]i but not with serum magnesium. 
[Mg]i levels are low in patients undergoing cardiac surgery and those 
with AMI. Intravenous magnesium sulfate corrects low [Mg]i levels in 
AMI patients. Energy-dispersive x-ray analysis determination of 
sublingual cell [Mg]i may expedite the investigation of the role of 
magnesium deficiency in heart disease (24). 
Lower than normal dietary intake of Mg can be a strong risk factor 
for hypertension, cardiac arrhythmias, ischemic heart disease, 
atherogenesis and sudden cardiac death. Deficits in serum Mg 
appear often to be associated with arrhythmias, coronary vasospasm 
and high blood pressure. Evidence is accumulating for a role of 
Mg2+ in the modulation of serum lipids and lipid uptake in 
macrophages, smooth muscle cells and the arterial wall. Shortfalls in 
the dietary intake of Mg clearly exist in Western World populations, 
and men over the age of 65 years, who are at greatest risk for 
development and death from ischemic heart disease, have the 
greatest shortfalls in dietary Mg. It is becoming clear that Mg exerts 
multiple cellular and molecular effects on cardiac and vascular 
smooth muscle cells which explain its protective actions (25). 
Short-term (S-T) dietary deficiency of magnesium (Mg) (21 days) 
in rats would: 1) result in reduction in serum(s) sphingomyelin (SM) 
and changes in several blood lipids, HDL-cholesterol (HDL-C) and 
phosphatidylcholine (PC) concomitant with elevations in s cholesterol 
(chol), s LDL+VLDL and trigycerides (TG), as well as reduction in the 
PC/cholesterol ratio; 2) lead to oxidative stress, characterized by 
reductions in glutathione (glut) content in the various chambers of 
the heart and activation of e-NOS and n-NOS in the atria, ventricles 
and aortic smooth muscle (ASM); 3) produce early cardiac damage 
characterized by leakage of creatine kinase (CK) and lactic 
dehydrogenase (LDH); and 4) demonstrate that these 
pathophysiological changes are a result of profound reductions in s 
ionized Mg (Mg(2+)) and activation of the SM-ceramide pathway (26).  
Magnesium may be important in the pathogenesis of coronary 
heart disease and sudden death. Magnesium dilates both the 
epicardial and resistance coronary arteries in humans. Furthermore, 
the coronary arterial response to magnesium is dose dependent and 
independent of EDNO (27). 
The significance of magnesium has been debated because of 
difficulty in accurate measurement and other associated factors, 
including other electrolyte abnormalities. The serum magnesium 
level represents < 1% of total body stores and does not reflect total-
body magnesium concentration, a clinical situation very similar to 
that of serum potassium. Magnesium is important as a cofactor in 
several enzymatic reactions contributing to stable cardiovascular 
hemodynamics and electrophysiologic functioning. Its deficiency is 
common and can be associated with risk factors and complications 
of heart failure. Typical therapy for heart failure (digoxin, diuretic 
agents, and ACE inhibitors) are influenced by or associated with 
significant alteration in magnesium balance. The intricate role of 
magnesium on a biochemical and cellular level in cardiac cells is 
crucial in maintaining stable cardiovascular hemodynamics and 
electrophysiologic function. In patients with congestive heart failure, 
the presence of adequate total-body magnesium stores serve as an 
important prognostic indicator because of an amelioration of 
arrhythmias, digitalis toxicity, and hemodynamic abnormalities (28). 
Magnesium (Mg) plays an essential role in a wide range of 
fundamental cellular reactions in patients with ischemic heart 
disease. It has been well known that Mg plays a pivotal role in 
control of cardiac excitability, neuromuscular transmission, 
vasomotor tone, and blood pressure, among other functions. 
Especially, many epidemiological, experimental, and clinical studies 
support a pathological role for Mg in the etiology and development of 
major coronary risk factors as diabetes mellitus, hypertension, and 
hyperlipidemia as well as ischemic heart disease. Furthermore, the 
therapeutic value of Mg in the management of coronary risk factors 
and ischemic heart disease has been clarified. Dietary Mg 
supplementation should be considered as a preventive element in 
atherosclerosis and ischemic heart disease (29). 
 1.0 and 2.0 mM Mg2+ inhibits the tonic contraction and that 8.0 
mM Mg2+ inhibits the periodic as well as the tonic contraction of 
isolated human coronary arteries. Diltiazem inhibits the periodic 
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contraction, whereas nitroglycerin suppresses tonic contraction 
without affecting the periodic contraction (30). 
The use of high dose magnesium as first line drug therapy for 
OHCA was not associated with a significantly improved survival. 
Early defibrillation remains the single most important treatment for 
ventricular fibrillation (VF). Further studies are required to evaluate 
the role of magnesium in cardiac and cerebral resuscitation (31). 
Deficiency and efficiency of some essential micronutrients may play 
a role in the development of heart disease. The micronutrient 
supplements containing K+ and Mg(2+) may be beneficial, but 
because of potential risks, use should be carefully monitored and 
restricted to men taking potassium-losing diuretics (32). 
Intravenous administration of magnesium has proved to have 
beneficial effect in acute myocardial infarction. Magnesium seems to 
act at different levels of the cardiovascular system. Of the greatest 
importance is the direct influence of Mg2+ on the cardiomyocyte 
which includes: reduction of cytoplasmatic calcium overload, 
protection of mitochondria against calcium influx, and diminution of 
cellular potassium, magnesium and ATP depletion. By means of 
these effects, or by its direct action on myocardium, Mg2+ inhibits 
the origin of postinfarctional dysrhythmias. Further more, 
magnesium reduces afterload by decrease in vascular resistance, 
and improves coronary flow (33). 
Intravenous magnesium therapy may reduce mortality in patients 
with acute myocardial infarction. Further large scale trials to confirm 
(or refute)these findings are desirable (34). 
Magnesium infusion during a coronary occlusion has a significant 
benefit in reducing the IS in this model. Magnesium may have a 
beneficial clinical role in AMI, especially if administered before 
reperfusion as a bolus followed by a constant infusion (35). 
Magnesium administration has an infarct size limiting effect 
independent of its effects on myocardial oxygen consumption and 
incidence of arrhythmia in rabbits. The infarct size limiting effect of 
magnesium is attributable, at least in part, to augmentation of 
adenosine mechanism (36). 
The cardiovascular actions of the magnesium ion at 
pharmacological concentrations include coronary and systemic 
vasodilatation, platelet inhibition, and antiarrhythmic effects. 
Magnesium has also been reported to protect myocardial tissue in 
experimental models of ischaemia and reperfusion. The side-effects 
of magnesium treatment were transient flushing, related to speed of 
injection of the loading dose, and an increased incidence of sinus 
bradycardia (2p=0·02). Exploratory subgroup analyses of 28-day 
mortality did not indicate any effect modification by thrombolysis or 
aspirin, or by previous treatment with beta blockers, calcium 
antagonists, or diuretics. Intravenous magnesium sulphate is a 
simple, safe, and widely applicable treatment. Its efficacy in reducing 
early mortality of myocardial infarction is comparable to, but 
independent of, that of thrombolytic or antiplatelet therapy (37). 
It has recently been suggested that intravenous infusion of 
magnesium may reduce mortality and the incidence of serious 
arrhythmias in patients with ischaemic heart disease and acute 
myocardial infarction. Magnesium infusion was accompanied by a 
significantly increased incidence of atrioventricular conduction 
disturbances. The results suggest that patients suffering from acute 
ischaemic heart syndromes do not benefit from intravenous 
magnesium supplementation (38). 
MAGNESIUM IN RENAL FAILURE 
 
Renal excretion is the major route of magnesium elimination from 
the body and a positive magnesium balance would be expected 
under conditions of renal insufficiency. While magnesium intoxication 
is a real hazard when magnesium-containing drugs are given, 
magnesium balance may be normal or even decreased in uraemic 
patients. This is usually due to decreased dietary intake combined 
with the impaired intestinal magnesium absorption which 
characterizes chronic renal failure. Impairment of magnesium 
absorption seems to be related to deficient synthesis of the active 
metabolite of vitamin D by the non-functioning kidney. Following the 
institution of chronic haemodialysis or continuous ambulatory 
peritoneal dialysis (CAPD) treatment, the major determinant of 
magnesium balance is the concentration of magnesium in the 
dialysate. Changes in the dialysate magnesium have been used to 
reduce the incidence of renal osteodystrophy, to alleviate uraemic 
pruritus, or to retard the development of arterial calcification in 
chronic renal disease. However, uncertainty about magnesium, 
calcium and parathyroid hormone relationships in renal failure makes 
a reasoned approach to such manipulations extremely difficult (39). 
Chronic metabolic acidosis decreased renal TRPM6 expression, 
increased Mg2_ excretion, and decreased serum Mg2_ 
concentration, whereas chronic metabolic alkalosis resulted in the 
exact opposite effects. In conclusion, these data suggest that 
regulation of Ca2_ and Mg2_ transport proteins contributes 
importantly to the effects of acid-base status on renal divalent 
handling (40). 
The kidney has a vital role in magnesium homeostasis and, 
although the renal handling of magnesium is highly adaptable, this 
ability deteriorates when renal function declines significantly. In 
moderate chronic kidney disease (CKD), increases in the fractional 
excretion of magnesium largely compensate for the loss of 
glomerular filtration rate to maintain normal serum magnesium levels. 
However, in more advanced CKD (as creatinine clearance falls <30 
mL/min), this compensatory mechanism becomes inadequate such 
that overt hypermagnesaemia develops frequently in patients with 
creatinine clearances <10 mL/min. Dietary calcium and magnesium 
may affect the intestinal uptake of each other, though results are 
conflicting, and likewise the role of vitamin D on intestinal 
magnesium absorption is somewhat uncertain. Although various 
studies have shown that patients with higher serum magnesium tend 
to have lower PTH levels, many of these suffer from methodological 
limitations. Finally, we examine the complex and often conflicting 
results concerning the interplay between magnesium and bone in 
uraemic patients. Although the exact role of magnesium in bone 
metabolism is unclear, it may have both positive and negative effects, 
and it is uncertain what the optimal magnesium levels are in uraemic 
patients (41). 
A number of factors affect the concentration and distribution of 
magnesium in patients with chronic renal failure (CRF). Poor 
nutritional intake, impaired absorption from the intestine, vomiting, 
diarrhea, the use of diuretics and acidosis may result in a negative 
balance. More commonly, accumulation of magnesium may be the 
consequence of reduced renal excretion (42).  
Magnesium is predominantly an intracellular cation that plays a 
critical role in cellular physiology. Serum levels are often slightly 
elevated in patients on chronic hemodialysis and older reports 
suggests that total body stores may also be increased, based on 
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bone biopsies in patients treated with higher dialysate magnesium 
levels than are currently in use today. Several studies have shown 
that magnesium, particularly in the form of magnesium carbonate, is 
an effective phosphate binder and can decrease patients' exposure 
to calcium. While short-term or adjuvant use of magnesium 
carbonate appears safe and effective as a phosphate binder, more 
studies are needed to evaluate the long-term effects on vascular 
calcification, bone histology, and mortality (43). 
The continued use of molecular techniques to probe the constitutive 
and congenital disturbances of magnesium metabolism will increase 
the understanding of cellular magnesium transport and provide new 
insights into the way these diseases are diagnosed and managed 
(44). 
 
MAGNESIUM IN LIVER DISEASE 
 
Six weeks of Mg supplementation did not increase muscle Mg, 
although Mg supplementation and spironolactone treatment were 
independent predictors of muscle Mg. The intervention had no effect 
on muscle strength and mass, but both increased during the study, 
probably owing to the general care (45). 
Magnesium deficiency can cause dyslipidemia and insulin 
hypersecretion, which may facilitate gallstone formation. However, 
the effect of long-term consumption of magnesium on the risk of 
gallstone disease is unknown, a protective role of magnesium 
consumption in the prevention of symptomatic gallstone disease 
among men (46). 
Cellular magnesium content is a better parameter when 
determining alterations in magnesium status in alcohol-induced 
diseases of the liver than plasma magnesium concentrations, which 
can still remain in the normal range even in severe forms of cirrhosis 
(47). 
Chronic terminal cirrhotics are magnesium depleted which should 
be taken into account in case of liver transplantation and also in 
other interventions. Spot sampled serum ionized magnesium 
revealed magnesium depletion poorly (48). 
The plasma levels of Zn and Mg were found to be reduced, as 
were the urine levels of Mg. Urine Zn, on the other hand, was higher 
than normal. Plasma Zn correlated inversely, and urine Zn directly, 
with the severity of the disease, rather than with alcohol consumption 
or treatment with diuretics (49). 
 
MAGNESIUM AND BOWEL DISEASE 
 
Mg deficiency is a frequent complication of inflammatory bowel 
disease (IBD) demonstrated in 13-88% of patients. Decreased oral 
intake, malabsorption and increased intestinal losses are the major 
causes of Mg deficiency. Twenty-four-hour urinary excretion of Mg is 
a sensitive index and should be monitored periodically. Parenteral 
Mg requirements in patients with IBD are at least 120 mg/day or 
more depending upon fecal or stomal losses. Oral requirements may 
be as great as 700 mg/day depending on the severity of 
malabsorption (50). 
Serum Mg levels were significantly lower in the Crohn's group 
than in a group of hospital controls; 5-10 mmol of IV Mg were 
required daily to prevent Mg depletion during IV nutrition and some 
patients required higher intakes. Three patients with particularly 
severe malabsorption required oral Mg supplements in the long-term. 
The rationale for using our method of assessing Mg status, and the 
importance of recognizing and treating chronic Mg deficiency are 
presented (51). 
Magnesium (Mg) deficiency increases genomic instability and Mg 
intake has been reported to be inversely associated with a risk of 
colorectal cancer (CRC). That organo-Mg inhibits inflammation-
related mouse colon carcinogenesis by modulating the proliferative 
activities and chromosomal instability of CRC and suppressing 
colonic inflammation may suggest potential use of organo-Mg for 
clinical chemoprevention trials of CRC in the inflamed colon (52). 
 
MAGNESIUM AND REPRODUCTIVE SYSTEM 
 
It has been revealed that low serum magnesium (Mg) is often 
associated with insulin resistance (IR), cardiovascular problems, 
diabetes mellitus, and hypertension. Patients with polycystic ovary 
syndrome (PCOS) are known to have a high incidence of insulin 
resistance. This study was designed to determine whether women 
with PCOS exhibit serum magnesium deficiency and its potential 
association with IR. The risk of PCOS for subjects with Mg deficiency 
was 19 times greater than those who had normal serum Mg 
concentrations (p ≤ 0.0001). No correlation was found between Mg 
and insulin sensitivity or secretion, FPG, dyslipidemias, and also 
androgen concentrations. After adjustment for calcium concentration 
the role of magnesium to predict PCOS attenuated and became non-
significant (β:-1.9, p: 0.7) (53). 
Further studies are needed to clarify the actual role of magnesium 
in the physiology of the male reproductive tract, especially its 
association with premature ejaculation (54). 
Decreased levels of magnesium gives rise to vasoconstriction from 
increased thromboxane level, increased endothelial intracellular 
Ca2+, and decreased nitric oxide. This may lead to premature 
emission and ejaculation processes. Magnesium is probably involved 
in semen transport. More research into the role of magnesium in the 
male physiology of reproductive tract, especially its association with 
premature ejaculation, is advocated (55). 
Contraction of smooth muscles of the vas deferens plays an 
important role in the propulsion of sperm into the pelvic urethra. 
Reactivity of the vas deferens to electrical stimulation is modulated 
by extracellular Mg2+ concentration. The possible relevance of these 
data to sperm transport through the vas deferens is discussed (56). 
No significant changes in sperm characteristics, blood ionized or 
total Mg, or ejaculate total Mg levels were detected. However, 
ejaculate ionized Mg levels increased in Group M from 0.18 ± 0.05 to 
0.30 ± 0.05 (mmol\\l\; mean ± SD, p <\; 0.05). Within the observation 
period of 3 months, one pregnancy occurred in the partner of a male 
from Group M. In conclusion, magnesium orotate treatment at a dose 
of 3000 mg\\day leads neither to a significant improvement of sperm 
variables nor does it increase the pregnancy rates of female partners 
of treated males as compared to those of controls. Thus, 
magnesium orotate treatment was not shown to be effective therapy 
for idiopathic male infertility (57). 
 
MAGNESIUM AND DEPRESSION 
 
The female subjects who were diagnosed with  clinical 
depression and premenstrual dysphoric disorder were treated with 
daily dose of  360 mg. of magnesium. Depression was evaluated 
for three months. Nearly all the female  patients responded 
positively to the magnesium therapy with elevation of mood,  
relaxation and sleep duration (58). 
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The incidence of depression is increasing worldwide. Much is still 
unknown about the possible role of magnesium in depression 
prevention and treatment. Magnesium has an effect on biological 
and transduction pathways implicated in the pathophysiology of 
depression. The possible role of magnesium in depression 
prevention and treatment remains unclear. Magnesium seems to be 
effective in the treatment of depression but data are scarce and 
incongruous. Disturbance in magnesium metabolism might be 
related to depression. Oral magnesium supplementation may 
prevent depression and might be used as an adjunctive therapy. 
However, more interventional and prospective studies are needed in 
order to further evaluate the benefits of magnesium intake and 
supplementation for depression (59). 
Depressive symptoms are frequent in students and may lead to 
countless problems. Several hypotheses 
associatemagnesium with depression because of the presence of 
this mineral in several enzymes, hormones, and neurotransmitters, 
which may play a key role in the pathological pathways of depression. 
The aim of this study was to assess whethermagnesium intake could 
modulate depressive symptoms (60).  
That hypomagnesaemia could be an epiphenomenic biochemical 
trait in less drug-responsive depressed patients. It is also plausible 
that lower Mg levels and hyperactive traits identify a biological 
subtype of patients with increased catecholaminergic functioning and 
a poorer response to aminergic drugs. Moreover, Mg depletion could 
partly account for the correlation between low Mg levels and poor 
outcome and this raises the question of Mg's possible 
therapeutic role in depression (61). 
Numerous studies have been performed on magnesium (Mg) 
metabolism in patients with mood disorders but consistent results 
have not been obtained. A relationship between catecholamines and 
Mg metabolism has been described and our results support the 
hypothesis that hypermagnesaemia might lead to hypoactivity and 
psychomotor retardation which is so often observed in depressed 
patients (62). 
A higher magnesium intake has been related to 
lowerdepressive symptoms. However, epidemiological evidence on 
this issue is scarce (63).  
There is more than sufficient evidence to implicate inadequate 
dietary magnesium as the main cause of TRD, and that physicians 
should prescribe magnesium for TRD. Since inadequate brain 
magnesium appears to reduce serotonin levels, and since anti-
depressants have been shown to have the action of raising brain 
magnesium, we further hypothesize that magnesium treatment will 
be found beneficial for nearly all depressives, not only TRD (64). 
 
MAGNESIUM AND CANCER 
 
The relationship between magnesium and cancer is not as 
simple as could be assumed from the well-established requirement 
of magnesium for cell proliferation. Basic and pre-clinical studies 
indicate that magnesium deficiency can have both anti- and pro-
tumour effects. The role of magnesium in cancer is also critically 
examined with regard to mitochondrial function, apoptosis and 
resistance to treatment. Finally, we bring together the latest 
experimental evidence indicating that alteration in the expression 
and/or activity of magnesium channels is a frequent finding in cancer 
cells and human tumour tissues examined to date, and we discuss 
the potential implications for developing novel diagnostic and 
therapeutic strategies (65). 
A complex relationship links magnesium and cancer. 
Impaired magnesium homeostasis is reported in cancer patients, and 
frequently complicates therapy with some anti-cancer drugs. More 
studies should be undertaken in order to disclose whether a simple 
and inexpensive intervention to optimize magnesium intake might be 
helpful in the prevention and treatment of cancer (66). 
Relationship between magnesium and cancer is complex. In mice 
inoculated with LLC cells and receiving low-magnesium diet, a higher 
metastatic potential was observed as compared to control mice. In 
conclusion, our results demonstrate a direct role of magnesium in 
tumor growth and also point at deleterious effect of 
lowmagnesium status on tumor metastasis (67). 
Magnesium is involved in a wide range of biochemical reactions that 
are crucial to cell proliferation, differentiation, angiogenesis, and 
apoptosis. Changes in magnesium availability have been shown to 
influence biological responses of immuno-inflammatory cells. Equally 
plausible seems to be an involvement of magnesium in the multistep 
and interconnected processes that lead to tumor formation and 
development; however, the "how" and "when" of such an 
involvement remain to be defined. Here, we reviewed in vitro and in 
vivo data that indicated a role for magnesium in many biological and 
clinical aspects of cancer (68). 
Low Magnesium (Mg)-containing diet reversibly inhibits the growth 
of primary tumors that develop after the injection of Lewis lung 
carcinoma (LLC) cells in mice. The inhibition of LLC tumor growth in 
Mg-deficient mice is due to a direct effect of low Mg on LLC cell 
proliferation and to an impairment of the angiogenic switch. We also 
observed an increase of nitric oxide synthesis and oxidative DNA 
damage. Complementary DNA arrays reveal that Mg deficiency 
modulates tumor expression of genes involved in the control of cell 
cycle, stress response, proteolysis, and adhesion. Our results 
suggest that Mg has multiple and complex roles in tumor 
development (69). 
Many studies have investigated the relation between magnesium 
and iron intake and diabetes and, separately, between diabetes and 
pancreatic cancer. A statistically significant inverse relation was 
noted between magnesium and pancreatic cancer for subjects with a 
body mass index of _25 kg/m2 (RR ¼ 0.67, 95% CI: 0.46, 0.99; P-
trend ¼ 0.04). Although, overall, no relation between magnesium or 
iron intake and pancreatic cancer was observed in this cohort of men, 
an inverse association with magnesium was suggested among 
overweight individuals, which should be examined in other studies 
(70). 
Mg deficiency increases susceptibility to chemical oncogens. The 
abnormal metabolism of tryptophan (yielding a carcinogenic 
metabolite) that indicates functional or absolute pyridoxine deficiency 
is an indirect clue to Mg deficiency. Vitamin 8 8-activated enzymes 
require Mg as a cofactor. However, the early warnings against the 
use of Mg as part of an antineoplastic program against established 
cancer were justified, since rapidly metabolizing cells (such as 
cancers) are dependent on Mg. There arc similarities between 
experiences with Mg and with Se and Zn. All three arc required for 
normal metabolism; Se also protects against free radicals in the 
environment. Mg and Zn have increased established tumor growth, 
and their depletion has been applied to antineoplastic programs, with 
risks comparable to those of using anti metabolic agents (71). 
The main target in the relationship between Mg and metals in 
carcinogenesis is either membrane as regards Pb and Cd, or 
nucleus as regards Pt, Ga, Co and Ni. The ideal treatment of Mg 
disturbances in carcinogenesis should control the factors which 
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regulate cellular and subcellular Mg distribution in neoplastic tissues 
as well as those which avoid Mg depletion in extra malignant tissues 
(72). 
The possible association between the risk of ovarian cancer and 
the levels of calcium and magnesium in drinking water from 
municipal supplies was investigated in a matched case control study 
in Taiwan. There may be a significant protective effect of magnesium 
intake from drinking water on the risk of ovarian cancer death (73). 
 
MAGNESIUM , BONE DISEASE & OSTEOPOROSIS  
 
Dietary Mg intake has been linked to osteoporosis. Previous 
studies have demonstrated that severe Mg deficiency [0.04% of 
nutrient requirement (NR)] results in osteoporosis in rodent models. 
Mg intake of 10% of NR in rats causes bone loss that may be 
secondary to the increased release of substance P and TNF-α (74). 
 
MAGNESIUM AND THYROID 
 
Training until exhaustion causes reduction in thyroid hormone 
activity in sedentars and sportsperson. It has been established that 
Mg supplementation however, prevents reduction in thyroid hormone 
activity in sedentars and sportsperson (75). 
Plasma and RBC Mg concentrations were low in half of the 
hyperthyroid subjects, but mean values were not significantly 
different from controls. Urinary excretion and clearance of Mg were 
lower in hypothyroid subjects, but differences were removed when 
expressed relative to Cr excretion and clearance (76). 
Magnesium supplementation decreased the elevated total 
cholesterol and triglyceride concentrations of the diabetic rats to the 
control level. It was concluded that oral magnesium supplementation 
might decrease the diabetes-induced disturbances of lipid 
metabolism (77). 
Serum T4 response to TRH challenge was significantly reduced in 
Mg-deficient as compared to Mg-adequate rats at all time intervals. 
The reduction of T4 level could be due to an impaired T4 synthesis 
or release in Mg-deficient rats (78) 
Plasma magnesium concentration was elevated by acute MgCl2 
infusions to determine the reabsorptive capacity 
of magnesium.Thyroid deficient rats reabsorbed 15-30% more of the 
filtered magnesium at any given plasma concentration. 
Thyroid hormone has a direct effect on the tubule which if chronically 
absent results in subtle sodium and calcium wasting and renal 
retention of magnesium. Administration of thyroid hormone to 
euthyroidorthyroid deficient rats twenty-four hours prior to 
experimentation had no effect on calcium and magnesium handling 
(79). 
 
MAGNESIUN AND ADRENAL GLAND 
 
Magnesium ion (Mg) directly inhibits aldosterone production in 
rat adrenal glomerulosa cells, while potassium ion directly stimulates 
aldosterone production. It is reported that Mg shows 
antihypertensive effect in patients with essential hypertension. 
Secondary hyperaldosteronism induced by diuretic treatment in 
patients with congestive heart failure accelerates potassium 
and magnesium ions' excretion in urine. Aldosterone antagonists, 
such as spironolactone and eplerenone, correct not only potassium 
deficiency but also magnesium deficiency induced by diuretics. Mg 
supplementation also may be useful procedure to correct potassium 
and magnesium deficiency, because Mg itself inhibits aldosterone 
release from the adrenal glands (80). 
MgSO4 showed an inhibitory effecton aldosterone production 
stimulated by angiotensin II (10pM to 10nM), whereas it had no 
significant effect on aldosterone production due to ACTH stimulation 
(10pM to 10nM). These data suggest that magnesium has an 
inhibitory action on aldosterone production in vitro and may be a 
physiological regulator of aldosterone production (81). 
 
MAGNESIUM AND IMMUNE FUNCTION 
 
Epidemiological and experimental studies underline the role 
of magnesium in inflammation. Several data indicate an 
enhanced response of phagocytes (granulocytes, macrophages) 
derived from magnesium-deficient animals or cultured under 
low magnesium conditions to the inflammatory mediators' stimulation. 
Magnesium status is an important modulator of the 
phagocyte response to immune stimuli and consequently could be 
implicated in a wide range of pathophysiological issues, e.g. those 
related to the production of radical oxygen species (ROS). It is likely 
that magnesium directly modulates phagocyte priming by its calcium 
antagonism and indirectly by its effect on the immunoinflammatory 
processes, the source of the priming mediators (82). 
Experimental magnesium deficiency in the rat induces after a few 
days a clinical inflammatory syndrome characterized by leukocyte 
and macrophage activation, release of inflammatory cytokines and 
acute phase proteins, excessive production of free radicals. Increase 
in extracellular magnesium concentration, decreases 
inflammatory response while reduction in the 
extracellular magnesium results in cell activation. 
Magnesium deficiency contributes to an 
exaggerated response to immune stress and oxidative stress is the 
consequence of the inflammatory response. Inflammation is the 
missing link to explain the role of magnesium inmany pathological 
conditions (83). 
Magnesium status is a well-known modulator of the immune system. 
Magnesium is an important modulator of immune cell function under 
in vitro conditions. However, a magnesium supplementation seems 
to be unable to prevent any exercise-associated alterations in 
immune cell function in athletes with balanced magnesium status 
(84).  
Recent findings regarding roles for magnesium in immune 
competence confirm and extend previous knowledge of its 
participation in natural and adaptive immunity. The detrimental 
effects of severe magnesium deficiency have been confirmed. There 
is better comprehension of how magnesium relates to mechanisms 
that control cellular activities and regulate interactions among cells 
that affect immune functions (85). 
Physical exercise may deplete magnesium, which together with a 
marginal dietary magnesium intake may impair energy metabolism, 
muscle function, oxygen uptake and electrolyte balance. 
Magnesium deficiency leads to immunopathological changes that are 
related to the initiation of a sequential inflammatory response. 
Although in athletes magnesium deficiency has not been 
investigated regarding alterations in theimmune system, the 
possibility exists that magnesium deficiency could contribute to the 
immunological changes observed after strenuous exercise (86). 
In athletes, exercise leads to the exhaustion of magnesium and 
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consequently to the decline of immune function (87). 
 
MAGNESIUM AND ALCOHOL CONSUMPTION 
 
Clinical and experimental evidence indicates alcohol 
consumption as one of the major causes of magnesium loss from 
several tissues. As a result of this loss, serum magnesium tends to 
decrease while urinary magnesium excretion increases 2-3 fold. 
Experimental data confirm that chronicconsumption of 6% ethanol in 
the Lieber De-Carli diet for 3 weeks results in a marked decrease in 
total tissue magnesium content in rats. This decrease affects brain, 
liver and all skeletal muscle, including heart, to a varying extent. 
Ethanol impairs magnesium transport and homeostasis in brain, 
brain vasculature, skeletal muscle, heart and liver cells, as a first 
step towards more mechanistic studies aimed at 
relating magnesium loss with the incurrence of short- and long-term 
ethanol-induced complications in these organs (88). 
Acute and chronic ethanol administration results in a decrease in 
cellular Mg2+ content and an alteration of Mg2+ transport in liver 
cells. The defect in hormone-activated Mg(2+) transport observed in 
the chronic EtOH model [Young, A., Cefaratti, C., & Romani, A. 
(2003). Chronic EtOH administration alters liver Mg2+ homeostasis. 
Am J Physiol 284, G57-G67] depends not only on a reduced cellular 
Mg2+ content but also on the impaired Mg2+ transport mechanisms 
present in the hepatocyte plasma membrane, in particular the Mg2+ 
entry pathway, which prevents the liver cell from restoring cellular 
Mg2+ homeostasis (89). 
A significantly higher, alcohol dose-related excretion of Mg and 
Ca (calcium) in the urine after the oral Mg load among consumers 
ofalcohol. Although the study is based on a small number of subjects 
with differences in smoking habits, it is suggested that alcohol 
consumption even in moderate amounts could contribute to Mg 
deficiency (90). 
Moderate consumption of ethanol lowers mortality from coronary 
artery disease, and one of the possible mechanisms is an 
antiarrhythmic action. In the group consuming beer, whose 
plasma magnesium rose from 0.89 (SD 0.01) to 0.98 (SD 0.02) 
mmol/L (P < 0.0025). This level of beer consumption did no obvious 
harm to liver function and its possibly beneficial effect on 
plasma magnesium deserves further investigation (91). 
Alcohol-induced cellular loss of [Mg2+]i is associated with cellular 
Ca2+ overload and generation of oxygen-derived free radicals; 
chronic pretreatment with vitamin E prevents alcohol-induced 
vascular injury and pathology in the brain (92). 
A comprehensive and critical review of the evidence 
relating magnesium (Mg) deficiency to alcohol consumption reveals 
several important types of interactions. A number of aspects of the 
clinical syndrome of alcoholism contribute to and intensify that 
already existing reduction in body Mg stores. Relatively little attention 
has been paid to the possible value of Mg administration as a 
preventive measure to forestall or minimize the deleterious effects of 
chronic use of alcohol or to prevent the development of cancer than 
can occur in this setting (93). 
Increased intracellular calcium, which was partly due 
to magnesium depletion and suppressed sodium pump activity, and 
expanded body fluid volume, had a possible role in the development 
of alcohol-induced hypertension. It is also suggested that 
oral magnesiumsupplementation had a hypotensive effect 
on alcohol-induced hypertension possibly through decreased 
intracellular sodium concentration caused by an activation of sodium 
pump and decreased sympathetic nervous activity (94). 
Alcohol has been shown to reduce serum calcium concentrations 
in several animal studies. There was an inversely related diminuition 
of serum calcium and magnesium concentrations with increasing 
serum alcohol. These effects of alcohol may play a role in the 
metabolic and clinical disorders observed in severely intoxicated 
people (95). 
Although alcohol has long been known to induce cardiac 
depression and cardiomyopathy, it is not known whether drug 
therapy or pharmacologic manipulation can be used to prevent or 
reverse these toxicities. High [Mg2+] (15 mM) given either before or 
during ethanol-induced cardiotoxicity is effective in attenuating both 
functional and metabolic damage caused by high ethanol perfusion 
in the rat heart (96). 
 
MAGNESIUM AND GENETIC DISORDERS 
 
The continued use of molecular techniques to probe the 
constitutive and congenital disturbances of magnesium metabolism 
will increase the understanding of cellular magnesium transport and 
provide new insights into the way these diseases are diagnosed and 
managed (97). 
Ionic magnesium (Mg2+) depletion has long been known to 
cause hyperexcitability with convulsive seizures in rodents, effects 
that have been reversed by treatment with magnesium (Mg). 
Hyperexcitable children have low ERC-Mg with normal serum 
Mg2+ values, and that Mg2+/vitamin B6 supplementation can restore 
normal ERC-Mg levels and improve their abnormal behavior (98). 
 
CONCLUSION 
 
This paper has covered a wide range of research findings in the 
areas of magnesium linking its significance in the restoration of 
various health and clinical symptoms. Most of the research findings 
compiled in this paper refers to studies carried out on humans with 
very few on animals. Taking into account the enormous role of 
magnesium in the regulating nearly 300 enzyme activities, this 
review article may have missed certain findings and therefore the 
authors recommend further up gradation of the role of magnesium in 
human health and disease. 
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